Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia

This study has been completed.
Stanford University
Information provided by (Responsible Party):
Department of Veterans Affairs Identifier:
First received: July 25, 2007
Last updated: August 29, 2013
Last verified: August 2013

The purpose of this study is to determine if replacing melatonin function with a melatonin agonist (ramelteon) in individuals that lack endogenous melatonin production (tetraplegia) helps to alleviate self-reported sleep disruption.

Condition Intervention Phase
Spinal Cord Injury
Sleep Disorders
Drug: Ramelteon
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Melatonin Replacement for Treatment of Sleep Disruption

Resource links provided by NLM:

Further study details as provided by Department of Veterans Affairs:

Primary Outcome Measures:
  • Improvement in subjective and objective sleep parameters [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improvement in daytime alertness and overall quality of life. [ Time Frame: 10 weeks ] [ Designated as safety issue: No ]

Enrollment: 60
Study Start Date: July 2007
Study Completion Date: July 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Drug: Ramelteon
8 mg nightly
Other Name: Rozerem
Placebo Comparator: Arm 2
Drug: Placebo
Nightly 8mg of placebo (same appearance as ramelteon)


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 years or older, male or female veterans of any racial or ethnic group
  • Neurologically complete (Frankel A or B) damage to the lower (C4-C8) cervical spinal cord
  • Absence of melatonin production
  • Time since SCI is greater than 6 months [no cases of acute SCI]
  • Subjective complaint of sleep disruption

Exclusion Criteria:

  • Current use of fluvoxamine (Luvox , antidepressant), rifampin (antimycobacterial), ketoconazole (Nizoral , antifungal), or fluconazole (Diflucan , antifungal) [these interact with the same liver enzyme that is the primary metabolizer of ramelteon]; use of sleep medications is okay
  • Hepatic dysfunction
  • Concomitant use of over-the-counter melatonin
  • Pregnancy or breast feeding
  • Currently or have within the past six months met DSM-IV criteria for drug or alcohol abuse or dependence or AUDIT score >19
  • Acute illness or unstable chronic illness. Use of continuous positive airway pressure (CPAP) for treatment of sleep apnea is acceptable.
  • No travel across three or more time zones within three weeks or during the protocol
  • Illiterate or unable to read or write English or are judged by the investigator to be unable or unlikely to follow the study protocol
  Contacts and Locations
Please refer to this study by its identifier: NCT00507546

United States, California
VA Palo Alto Health Care System
Palo Alto, California, United States, 94304-1290
Sponsors and Collaborators
Stanford University
Principal Investigator: Jamie M. Zeitzer, PhD VA Palo Alto Health Care System
  More Information

No publications provided

Responsible Party: Department of Veterans Affairs Identifier: NCT00507546     History of Changes
Other Study ID Numbers: B6010-R, 06-038R
Study First Received: July 25, 2007
Last Updated: August 29, 2013
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
spinal cord injury

Additional relevant MeSH terms:
Sleep Disorders
Spinal Cord Injuries
Sleep Initiation and Maintenance Disorders
Wounds and Injuries
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Mental Disorders
Spinal Cord Diseases
Central Nervous System Diseases
Trauma, Nervous System
Sleep Disorders, Intrinsic
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Molecular Mechanisms of Pharmacological Action
Protective Agents processed this record on April 17, 2014